Studying Fentanyl in Patients With Cancer
TerminatedNCT00899951
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
RATIONALE: Studying blood samples from cancer patients undergoing pain treatment in the laboratory may help doctors learn more about how pain drugs work in the body. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at fentanyl in patients with cancer.
Study details
- Official title
- Pharmacokinetics of Continuous Infusion Fentanyl in Cancer Patients
- Conditions
- Brain and Central Nervous System Tumors
- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- Lymphoproliferative Disorder
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms
- Pain
- Precancerous Condition
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Drug: fentanyl citrate
- Other: pharmacological study
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Collaborators
- National Cancer Institute (NCI)
- Start date
- 2007-10
- Primary completion
- 2009-07
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
DISEASE CHARACTERISTICS: * Diagnosis of cancer * Inpatient at the Johns Hopkins Hospital Cancer Center undergoing pain treatment with continuous infusion fentanyl citrate for ≥ 5 days PATIENT CHARACTERISTICS: * Willing to change to an alternative opioid PRIOR CONCURRENT THERAPY: * See Disease Characteristics * At least 72 hours since transdermal fentanyl citrate administration * At least 12 hours since transmucosal fentanyl citrate administration * No known requirement for continued opioid therapy with any fentanyl citrate products after discontinuation of fentanyl citrate therapy
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00899951